Study of Dapagliflozin With Standard ESA Therapy in Adults With Anemic Chronic Kidney Disease

What this Trial Is About

Researchers are evaluating the effects of dapagliflozin, a sodium-glucose co-transporter 2 SGLT2 inhibitor, in patients with chronic kidney disease CKD who also have anemia. This phase 2 clinical trial aims to explore whether dapagliflozin can improve responsiveness to erythropoiesis-stimulating agents ESA in treating anemia associated with CKD. Previous studies have suggested that SGLT2 inhibitors may increase hemoglobin and hematocrit levels, potentially benefiting patients with anemia due to CKD. Participants will be randomly assigned to one of two groups one group will receive dapagliflozin 10 mg tablets once daily along with standard ESA therapy, while the other group will receive only the standard ESA therapy. The treatment period lasts 12 weeks. This trial uses a double-blind design to compare the effects of adding dapagliflozin to standard care against standard care alone. Throughout the 12-week study, participants will be monitored regularly to assess changes in the dose of ESA therapy needed and changes in hemoglobin levels. Researchers will evaluate these outcomes to determine how dapagliflozin impacts anemia management in CKD patients. Safety will also be monitored, and participation includes follow-up visits and assessments during the treatment period.

Impact of Dapagliflozin in Anemic Chronic Kidney Disease Patients